Ocugen opened lower at $0.92, compared with its previous close of $0.96. In the last trading session, the stock traded between $0.86 and $0.94. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Ocugen is now worth
$ 10.05
Resulting in a loss of
$ 89.95 (89.95%)
Note: Past profits do not guarantee future returns.
Rating from 5 Analysts
Today's Change
$-0.09 (-9.10%)
Day High
$0.94
Day Low
$0.86
Day Open
$0.92
Prev Close
$0.96
Volume
55,18,559
1W Return
-0.11%
1M Return
-7.81%
3M Return
-36.04%
6M Return
-41.01%
1Y Return
-34.36%
Market Cap ($ Mn)
296
PE Ratio
-
PB Ratio
-
PEG Ratio
-
ROE
-848.82%
ROCE
-157.58%
EPS (TTM)
$-0.01
1 Week
-0.11%
1 Month
-7.81%
3 Months
-36.04%
6 Months
-41.01%
9 Months
-38.09%
Ocugen Q3 Results: Sales beat estimate by 77.69%, EPS inline
Ocugen reported Q3 adjusted EPS of $(0.06), matching analyst consensus estimates. Quarterly sales of $1.951 million beat the $1.098 million estimate by 77.69%. Revenue grew 11.36% YoY from $1.752 million in the prior-year quarter. Losses narrowed 14.29% YoY from $(0.07) to $(0.06) per share.
8 days agoOcugen appoints Jolanda Crombach as general manager of European affiliate
Ocugen appoints Jolanda Crombach as General Manager of its new European affiliate. The Amsterdam-based office will support Phase 3 gene therapy programs and regulatory submissions. Crombach previously served as Managing Director of Moderna Netherlands. Key data readouts for OCU400, OCU410, and OCU410ST are expected in 2027 and 2028.
1mo agoOcugen Q2FY26 Results: Net loss widens to $0.07, opex up 18% YoY
Net loss widened to $0.07 per share in Q2 FY26 from $0.05 in Q2 FY25. Total operating expenses rose 17.8% YoY to $17.9 million, led by higher R&D spend. Cash runway extended into 2028 following $130 million convertible notes financing. FDA cleared Phase 3 trial for OCU410; enrollment completed for OCU400 and OCU410ST.
1mo agoOcugen secures provisional approval in Bahamas for OCU400 therapy
Ocugen secured provisional approval and priority designation from The Bahamas' LARTA Board for OCU400. Therapy will be supplied via expanded access program with first patient treatment targeted within 90 days. OCU400 targets mutations across more than 100 genes causing retinitis pigmentosa. Phase 3 topline data expected in 1Q 2027 with BLA submission planned for 2Q 2027.
1mo agoOcugen doses first patient in global Phase 3 trial for OCU410
Ocugen doses first patient in global Phase 3 trial for OCU410 gene therapy. Trial design aligned with FDA following successful Type B EOP2 meeting in July 2026. FDA granted RMAT designation, supporting potential accelerated approval pathway. Phase 2 data showed 31% reduction in lesion growth vs control at 12 months. Biologics License Application filing anticipated in 2028.
2mo agoOcugen to present OCU410 data and platform at September events
Ocugen Inc will present at three conferences in September 2026. CEO Dr. Shankar Musunuri to speak at Citi and H.C. Wainwright events. Dr. Raj K. Maturi to present 12-month Phase 2 data for OCU410. Focus includes geographic atrophy and inherited retinal diseases.
2mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in Ocugen is now worth
$ 10.05
Resulting in a loss of
$ 89.95 (89.95%)
Note: Past profits do not guarantee future returns.
